EGFR and non-small cell lung carcinoma: Results of a Phase 3 study in patients with stage IB to IIIA resected EGFR mutation–positive NSCLC, showed that disease-free survival (DFS) was significantly longer among those who received adjuvant therapy with osimertinib compared with those receiving placebo [13].